The role of N -glycans of HIV-1 gp41 in virus infectivity and susceptibility to the suppressive effects of carbohydrate-binding agents by Mathys, Leen & Balzarini, Jan
Mathys and Balzarini Retrovirology 2014, 11:107
http://www.retrovirology.com/content/11/1/107RESEARCH Open AccessThe role of N-glycans of HIV-1 gp41 in virus
infectivity and susceptibility to the suppressive
effects of carbohydrate-binding agents
Leen Mathys and Jan Balzarini*Abstract
Background: Carbohydrate-binding agents (CBAs) are potent antiretroviral compounds that target the N-glycans on
the HIV-1 envelope glycoproteins. The development of phenotypic resistance to CBAs by the virus is accompanied by
the deletion of multiple N-linked glycans of the surface envelope glycoprotein gp120. Recently, also an N-glycan on
the transmembrane envelope glycoprotein gp41 was shown to be deleted during CBA resistance development.
Results: We generated HIV-1 mutants lacking gp41 N-glycans and determined the influence of these glycan deletions
on the viral phenotype (infectivity, CD4 binding, envelope glycoprotein incorporation in the viral particle and on the
transfected cell, virus capture by DC-SIGN+ cells and transmission of DC-SIGN-captured virions to CD4+ T-lymphocytes)
and on the phenotypic susceptibility of HIV-1 to a selection of CBAs. It was shown that some gp41 N-glycans are
crucial for the infectivity of the virus. In particular, lack of an intact N616 glycosylation site was shown to result in
the loss of viral infectivity of several (i.e. the X4-tropic IIIB and NL4.3 strains, and the X4/R5-tropic HE strain), but
not all (i.e. the R5-tropic ADA strain) studied HIV-1 strains. In accordance, we found that the gp120 levels in the
envelope of N616Q mutant gp41 strains NL4.3, IIIB and HE were severely decreased. In contrast, N616Q gp41
mutant HIV-1ADA contained gp120 levels similar to the gp120 levels in WT HIV-1ADA virus. Concomitantly deleting
multiple gp41 N-glycans was often highly detrimental for viral infectivity. Using surface plasmon resonance
technology we showed that CBAs have a pronounced affinity for both gp120 and gp41. However, the antiviral
activity of CBAs is not dependent on the concomitant presence of all gp41 glycans. Single gp41 glycan deletions
had no marked effects on CBA susceptibility, whereas some combinations of two to three gp41 glycan-deletions
had a minor effect on CBA activity.
Conclusions: We revealed the importance of some gp41 N-linked glycans, in particular the N616 glycan which
was shown to be absolutely indispensable for the infectivity potential of several virus strains. In addition, we
demonstrated that the deletion of up to three gp41 N-linked glycans only slightly affected CBA susceptibility.
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The envelope of the human immunodeficiency virus
(HIV) carries two glycoproteins: the transmembrane
gp41 and the surface gp120, which are non-covalently
associated and both highly glycosylated. Gp120 con-
tains 18–31N-linked glycans of which about 56-73%
are suggested to be high-mannose-type glycans [1]. This
is unusual since cellular glycoproteins carry virtually* Correspondence: jan.balzarini@rega.kuleuven.be
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article, unless otherwise stated.exclusively complex-type glycans [2]. The transmembrane
gp41 contains 4–8N-linked glycosylation sites and all
4–5N-glycans on the ectodomain were suggested to be
complex-type glycans [3]. Together, the unusual dense
carbohydrate shield on the viral envelope prevents the
immune system to efficiently recognize the underlying
protein backbone and is therefore crucial for the success-
ful escape of the virus from the host immune system
[4-6]. Targeting the glycan shield is considered to be
more challenging than targeting proteins, due to the
high heterogeneity originating from glycosylation and
the pronounced flexibility of the glycans. However, itCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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(CBAs) (in particular those with a binding specificity
towards high-mannose-type glycans) are able to inhibit
HIV infection with a high efficiency and specificity
(reviewed in [7]). Additionally, these CBAs have been
shown to display a high genetic barrier, forcing the
virus to delete multiple N-glycans in its envelope glyco-
proteins in order to obtain significant phenotypic drug
resistance [8-14]. Interestingly, the deletion of these
N-glycans has been shown to increase the immunogen-
icity of the viral particle [14,15]. Therefore, CBAs may
not only offer direct antiviral effects but may also offer
indirect benefits, by the induction of an enhanced
immune response against the (mutant) virus.
In the process of gaining phenotypic CBA resistance,
HIV accumulates mutations in N-glycosylation sites on
the Env gene in the presence of escalating CBA concentra-
tions. In order to achieve significant levels of resistance to
CBAs, one or two single envelope N-glycan deletions are
often not sufficient, whereas a combination of several
N-glycan deletions is often required. It has been shown by
us and others that most, if not all of these glycan deletions
occur in gp120 [8-14]. However, we found at least one
N-glycan deletion in gp41 of HIV-1NL4.3 which appeared
under selection pressure by the combination of the plant
lectin Hippeastrum hybrid agglutinin (HHA) and the
carbohydrate-specific monoclonal antibody 2G12 [11]. It
was shown that the deletion of this glycan on N674 in
gp41 somewhat decreased the susceptibility of the virus
to several CBAs including the plant lectins HHA and
Galanthus nivalis agglutinin (GNA), the prokaryotic
lectin actinohivin (AH) and the non-peptidic antibiotic
pradimicin-S (PRM-S). However, the mutation N674D
had appeared in the context of virus selected in the
presence of CBAs (HHA+2G12), containing not only
the N674D mutation in gp41 but also 3 additional
N-glycosylation site mutations in gp120 (N160, N339
and N386 –according to HIV-1HXB2 amino acid number-
ing). Therefore, we wondered whether the sole deletion of
an N-glycan in gp41 could influence the susceptibility of
HIV-1 to CBAs, in the absence of glycan deletions in
gp120, which is so far considered to be the main target of
CBAs.
The gp41 N-glycans have already been studied by
others. However, since many of these reports contradictFP HR1 HR2
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Figure 1 Schematic representation of gp41 with indication of the N-li
HR2, heptad repeat 2; TM, transmembrane domain. Numbering was basedeach other [16-20], the exact role of the gp41 N-glycans
for HIV infection is still unclear.
The gp41 N-glycans might potentially play a role in
CBA susceptibility since it has been shown before that
some CBAs (i.e. AH and PRM-S), are able to bind gp41
in the absence of gp120 [21,22].
In order to gain more insight in the potential role of gp41
N-linked glycans in the antiviral activity of CBAs, we gener-
ated virus strains lacking individual (and combinations of)
N-linked glycans in gp41, using site-directed mutagenesis.
These mutant viruses were examined for their viral
phenotype (infectivity, CD4 binding, envelope glycopro-
tein expression on the virus particle and the transfected
cell, DC-SIGN-mediated capture and transmission of
captured virions to CD4+ T cells) and their sensitivity
towards a selection of highly active CBAs. In addition,
the binding kinetics of a selection of CBAs towards
gp41 were determined using the surface plasmon res-
onance (SPR) technology, to identify gp41 as potential
target for these compounds.
Results
Site-directed mutagenesis of N-glycosylation sites in
HIV-1NL4.3
A selection of N-glycosylation sites in HIV-1NL4.3 gp41
was studied on their influence on viral function and
susceptibility to the inhibitory effects of CBAs. It total,
we could reveal 7 different N-glycosylation sites in
HIV-1NL4.3 gp41, located on the asparagines 611, 616,
625, 637, 674, 750 and 816 (numbering of HIV-1HXB2
Env according to the HIV sequence compendium of
2013 [23]) (Figure 1). The glycosylation sites comprising
N611, N616 and N625 are found in the linker region be-
tween heptad repeat (HR) 1 and 2. The glycosylation site
containing N637 is located inside HR2, while N674 is
positioned between HR2 and the transmembrane domain
of gp41. The remaining two N-glycosylation motifs are
found in the cytoplasmic tail of gp41 (N750 and N816).
Since the CBAs with pronounced anti-HIV activity are
mostly high-molecular weight compounds which are not
passing the cell membrane, we focused on N-glycosyla-
tion sites in the extracellular portion of gp41 and deleted
these gp41 N-glycans using site-directed mutagenesis on
N611, N616, N625, N637 and N674 by replacing the
asparagine (N) by a glutamine (Q).TM
85 704
nked glycosylation sites. FP, fusion peptide; HR1, heptad repeat 1;
on the HIV sequence compendium 2013 [23].
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strains lacking individual gp41 N-glycans
In order to determine the importance of the individual
N-linked glycosylation sites on gp41 for the viral infectiv-
ity of HIV-1NL4.3, CD4
+ T-lymphocyte C8166 cells were
infected using equal viral loads of wild-type (WT) or gp41
N-glycan-deleted virus strains.
In a first experiment, virus was allowed to infect the cell
cultures and to replicate during 3 days, after which the
result of the viral infection (giant cell formation) was
quantified using light microscopy. Additionally, the pres-
ence of the enhanced green fluorescent protein (eGFP)
gene in the HIV-1NL4.3 virus used in the infection experi-
ments enabled the determination of eGFP expression by
fluorescence microscopy as a measurement of viral infec-
tion and replication. As is shown in Figure 2, infection
of C8166 cells with WT virus resulted in the appearance
of numerous giant cells and the abundant expression of
eGFP. Based on the microscopic observations, no marked
differences between infection with WT virus and infection
with the gp41 glycan-deleted mutants N625Q, N637Q
and N674Q gp41 HIV-1 strains could be observed.
However, infection with mutant N611Q gp41 HIV-1
resulted in a marked decrease in both giant cell forma-
tion and eGFP expression. The gp41 mutant N616Q
HIV-1 strain was seemingly without any viral infectivity
potential.
In a second experiment, the viral infectivity was quanti-
fied using flow cytometric determination of eGFP expres-
sion by the (mutant) virus-infected cells. Therefore, C8166
cells were infected and during 7 consecutive days, cell cul-
ture samples were harvested and analyzed. Figure 3A
shows the results of one (out of 5) representative experi-
ments, from which it became clear that there are differ-
ences in the infectivity of the WT and mutant HIV-1NL4.3
strains lacking one gp41 N-linked glycan. In order to
obtain more quantitative data, the slope of the curves was
calculated, starting from the data points at day 1 and end-
ing at the top of the infectivity curves (Figure 3B). It was
confirmed that the gp41 N616Q mutant HIV-1 lacked any
viral infectivity. The gp41 HIV-1 mutants N611Q and
N637Q also proved to have a decreased viral infectivity,
which was only significant for mutant N611Q. The other
mutants (N625Q and N674Q) had a viral infectivity not
different from WT virus.
Ability of WT and glycan-deleted HIV-1 strains to bind CD4
Given the fact that several mutant HIV-1NL4.3 strains
lacking individual gp41 N-glycans had a decreased or
even complete lack of viral infectivity, we wondered
whether this could be due to a deficient binding to the
primary receptor, CD4. Therefore, an enzyme-linked
immunosorbent assay (ELISA) to quantify the binding
efficiency of virus to soluble CD4 was performed(Figure 4). The results were normalized to WT virus
lacking envelope glycoprotein expression (WTΔEnv) to
account for aspecific protein-protein interactions. It
could be shown that the gp41 mutant N611Q, N637Q
and N674Q HIV-1 strains had a binding efficiency to
soluble CD4 (sCD4) that was not markedly different
from WT virus. However, the gp41 mutant N625Q
showed a non-significant increase (~130% of WT) in
binding efficiency. The mutant N616Q, which was earl-
ier shown to be uninfectious, was found to have a sig-
nificantly decreased CD4 binding (~5% of WT). These
findings may be explained by an altered gp120/gp41 con-
formation that does not efficiently recognize CD4 any-
more, or, alternatively, that the envelope of the mutant
gp41 N616Q virus virtually lacked glycoproteins in its
envelope.
Expression and incorporation of viral glycoproteins in WT
and mutant HIV-1NL4.3 strains lacking one N-linked glycan
in gp41
Given the lack of efficient CD4 binding by the mutant
gp41 N616Q virus, and since N-glycosylation plays a
crucial role during protein synthesis for correct enve-
lope glycoprotein folding, we examined the levels of
gp120 and gp41 in WT and mutant gp41 virus strains.
Therefore, virus was lysed and analyzed by Western
blot. Figure 5A visually shows that there is indeed
variation in the level of incorporated gp120 and gp41
in the mutant gp41 viruses, especially for the uninfec-
tious mutant gp41 N616Q virus which seems to have
an almost complete lack of viral envelope glycopro-
teins. The three panels of Figure 5A originated from
the same Western blot, shown in Additional file 1:
Figure S1. The data in Figure 5A were then quantified
and the levels of gp120 and gp41 were normalized to the
p24 capsid protein levels (Figure 5B). It was shown that all
mutants except for the N616Q mutant contained marked
levels of gp120 and gp41 in their envelope that were not
significantly different from the levels in WT virus. In
contrast, the mutant gp41 N616Q HIV-1 was shown to
have significantly decreased levels of gp120 and gp41 in
its envelope.
Flow cytometric analysis of gp120 incorporation in the
cell membrane of transfected HEK293T cells
In addition to the analysis of gp120 and gp41 levels in
viral particles, we also investigated the incorporation
of functional gp120 in the cell membrane. Therefore,
HEK293T cells were transfected to produce WT or
mutant gp41 HIV-1 particles. Gp120 on the cell mem-
brane was detected using the monoclonal antibody
2G12 that recognizes a glycosylated epitope on natively
folded gp120. As is shown in Figure 6 the deletion of
glycan N616 in gp41 resulted in a highly decreased
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Figure 2 Cytopathic effect of WT and mutant HIV-1NL4.3 on C8166 CD4
+ T cells. Cells were infected with equal amounts of virus, based on
the p24 capsid protein. Three days post infection, the (mutant) virus-infected cell cultures were inspected using light microscopy to visualize
syncytia formation and fluorescence microscopy to quantify eGFP expression.
Mathys and Balzarini Retrovirology 2014, 11:107 Page 4 of 18
http://www.retrovirology.com/content/11/1/107incorporation of gp120 in the cell membrane of the
transfected HEK293T cells. The other glycan deletions
in gp41 had no or only minor effects on gp120 incorp-
oration. These data are in agreement with the western
blot data on the gp120 levels in the virus particles
(Figure 5).Efficiency of virus capture by Raji/DC-SIGN cells and
efficiency of transmission of DC-SIGN-captured virions to
C8166 cells
In a first set of experiments, WT and mutant gp41 virions
(lacking individual gp41 N-glycans) were exposed to
DC-SIGN+ Raji cells, allowing the binding (capturing) of
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Figure 3 Infectivity of WT and mutant gp41 HIV-1NL4.3 strains. A. At day 0, CD4
+ T-lymphocyte C8166 cells were infected with comparable
viral loads, based on equal amounts of the p24 capsid protein. For 7 consecutive days, samples were harvested, fixed and analysed for eGFP
expression by flow cytometry. B. The infectivity as presented in panel A was quantified using a linear regression to part of the curves, starting at
day 1 post infection to the peak of the infectivity curve. Data are the means ± SEM of at least 5 independent experiments. The difference between WT
and mutant virus was considered to be significant when the p value calculated using the student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).
Mathys and Balzarini Retrovirology 2014, 11:107 Page 5 of 18
http://www.retrovirology.com/content/11/1/107DC-SIGN to gp120-containing virus. After elimination of
unbound virions, the amount of captured virus was quan-
tified using a p24 ELISA, as a measurement of the capture
efficiency by DC-SIGN. To control for alternative inter-
action pathways, not involving the recognition of gp120/
gp41 glycans by DC-SIGN, we included WT virus lacking
envelope glycoproteins (WTΔEnv). It was shown that this
virus had a capture efficiency of ~40% as compared to
WT virus (data not shown). We normalized all data to
WTΔEnv virus, to only take into account DC-SIGN-0
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Figure 4 Capacity of WT and mutant gp41 virus strains to bind
to sCD4. On average 48 ng p24 of the (mutant) HIV-1NL4.3 strains
was lysed using triton-X100 and brought into contact with ELISA
strips coated with sCD4. The binding efficiency was calculated after
normalization to WT virus lacking envelope glycoprotein expression
(to correct for aspecific interactions) and as relative to the binding of
WT virus (set at 100%). Data are the means ± SEM of at least 2 to 4
independent experiments. The difference between WT and mutant
was considered to be significant when the p value calculated using
the student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).mediated capture of WT versus mutant virus particles.
Figure 7A shows that the N611Q and N625Q mutant
gp41 virus strains were endowed with a capture efficiency
not significantly different from WT virus. The mutant
gp41 N616Q and N637 viruses had statistically lower cap-
ture efficiencies of ~80% and ~60%, as compared to WT
virus. In contrast, the mutant gp41 N674Q HIV-1 showed
a ~30% increase in capture efficiency.
In a second set of experiments, virus-captured DC-
SIGN+ Raji cells were brought into contact (co-cultured)
with C8166 cells, resulting in the transmission of cap-
tured virions from the Raji/DC-SIGN cells to the C8166
cells. The latter cells will then be infected and subse-
quently produce new virus particles. The production of
virus particles was quantified using a p24 ELISA and was
used as a measurement for the transmission efficiency.
Figure 7B shows that mutant virus strains containing the
N625Q and N637Q mutations in gp41 had transmission
efficiencies equal to WT virus. The mutant N674Q virus
strain had an increased transmission efficiency, while the
mutant N611Q showed a highly decreased transmission ef-
ficiency. The N616Q gp41 mutation resulted in a complete
absence of virus transmission, which is consistent with the
finding that this mutation was also highly detrimental on
virus infectivity, CD4 binding and envelope glycoprotein
expression. As expected, WTΔEnv also lacked transmis-
sion potential (data not shown).
Conservation of the gp41 N-glycosylation sites among
several HIV-1 subtypes
We found that at least one gp41 glycan (N616) was
indispensable for a wild-type-like viral phenotype of
HIV-1NL4.3 (efficient cell-free infection, CD4 binding,
envelope glycoprotein expression and transmission of
DC-SIGN-captured virus to CD4+ T-lymphocytes), and
the deletion of two other N-glycans (N611 and N637)
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Figure 5 Western blot analysis of expression and incorporation of gp120 and gp41 in the viral envelope of WT and mutant gp41 virus
strains. A. Analysis of the levels of gp120 and gp41 incorporation in virus particles. P24 was added to ascertain an equal-loading of the samples.
M: MagicMark XP Western protein standard (Novex). All 3 panels are part of the same original blot (Additional file 1: Figure S1). B. Relative protein
levels as quantified based on panel A using the ImageJ software, presented as normalized to p24 levels. Data are the means ± SEM of at least 5
independent experiments. The difference between WT and mutant virus was considered to be significant when the p value calculated using the
student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).
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mutant HIV-1NL4.3 strains. Therefore, the conservation
of these glycosylation sites among different HIV-1 sub-
types was examined, which would confirm their import-
ance for the survival of the virus. We aligned consensus
sequences of gp41 of >200 different HIV-1 strains be-
longing to 19 different subtypes and found that the first
4 N-terminal gp41 glycosylation sites (N611, N616,
N624/N625 and N637) are highly conserved (Figure 8).0
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Figure 6 Flow cytometric analysis of gp120 incorporation in
the cell membrane of transfected HEK293T cells. HEK293T cells
were transfected to produce WT or gp41 mutant HIV-1NL4.3. After
3 days, gp120 on the cell surface was detected using the monoclonal
antibody 2G12. The percentage of gp120-expressing cells was
determined using flow cytometry. Data are the means ± SEM of 2
independent experiments. The difference between WT and mutant
virus was considered to be significant when the p value calculated
using the student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).The glycosylation site at position N674 was present in
3 out of 19 subtypes (A2, CRF04-cpx, CRF14-BG). The
N-glycosylation site involving residue N798 was only
found in HIV-1 subtype F1. The glycosylation site con-
taining residue N816 was found in 5 out of the 19 se-
quences, from subtypes B, F1, H, CRF11-cpx and
CRF12-BF. The glycosylation site of residue N824 was
found in the sequences of HIV-1 subtypes G, CRF02-
AG, CRF06-cpx and CRF14-BG. This analysis confirms
the importance of the glycosylation sites involving resi-
dues N611, N616 and N637. Additionally, the glycan on
asparagine 624/625 is 100% conserved and may there-
fore also be endowed with an indispensable function
for the virus. The remaining 4 glycosylation sites, of
which only two (N674 and N816) are present in HIV-
1NL4.3, are less conserved among the analyzed HIV-1
subtypes.
In the initial search for N-glycosylation sites in HIV-
1NL4.3 Env we found an additional N-glycosylation site
involving N750. This glycosylation motif was not shown
in the alignment presented in Figure 8. Taking a closer
look on the HIV 2013 sequence of the Env protein com-
pendium, we found that this glycosylation site is only
present in 2 out of the approximately 200 HIV-1 strains
included in this compendium. Therefore, we assume that
this N-linked glycosylation site is not essential for the
phenotype of HIV-1.
The effect of the N616Q glycan deletion in gp41 on the
infectivity and gp120 envelope levels of various HIV-1 strains
Deleting the N616 glycan in gp41 of HIV-1NL4.3 was
shown to result in a highly significant decrease in viral
infectivity (Figure 3). We also investigated the role of
this N-linked glycan in gp41 of other HIV-1 strains.
Therefore, we generated additional N616Q gp41 mutant
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Figure 7 Efficiency of virus capture by DC-SIGN+ Raji cells and the subsequent transmission of captured virus to C8166 T cells.
A. Raji/DC-SIGN cells were exposed to virus during 1 h, after which unbound virions were removed by thourough washing. The levels of
captured virus were quantified using a p24 ELISA and were used as a measurement for capture efficiency. All data were normalized to the
capture efficiency of virus lacking envelope glycoprotein expression (WTΔEnv). B. Virus-captured Raji/DC-SIGN cells were brought into contact
with C8166 T cells, resulting in transmission of virus to, and infection of, the C8166 cells. Virion production by the C8166 cells, as quantified by
p24 ELISA, was used as a measurement for transmission efficiency. Results represent transmission efficiency, normalized to equal levels of virus
capture by the Raji/DC-SIGN cells. Results are means ± SEM of at least 3 independent experiments. The difference between WT and mutant
gp41 virus was considered to be significant when the p value calculated using the student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).
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Figure 8 Conservation of N-linked glycosylation sites in gp41 of several HIV subtypes. An alignment of consensus sequences (2004) was
obtained from the HIV sequence database [23] and was analysed using the program N-glycosite [23] to predict N-linked glycosylation sites in
gp41. The alignment contained consensus sequences for HIV subtypes A1, A2, B, C, D, F1, F2, G, H, CRF01-AE, CRF02-AG, CRF03-AB, CRF04-cpx,
CRF06-cpx, CRF08-BC, CRF10-CD, CRF11-cpx, CRF12-BF, and CRF14-BG. The consensus of consensus sequences and the ancestral sequences were
excluded from the analysis. The fraction of HIV subtypes containing a glycosylation site at a specific location was determined. The positions
(HXB2 numbering) of the glycosylated asparines are incidated on top of the lines. Glycosylation sites that were absent in HIV-1NL4.3 are indicated
between parentheses.
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http://www.retrovirology.com/content/11/1/107virus strains (i.e. IIIB, ADA and HE). HIV-1IIIB is, as
NL4.3, a laboratory adapted HIV strain with a CXCR4
coreceptor tropism. The laboratory-adapted ADA strain
uses CCR5 as coreceptor. HE is a clinical isolate of a
Belgian HIV-1 patient. This virus strain is able to use
both coreceptors during HIV entry.
The gp41 N616Q mutant viruses were compared with
their WT counterparts to investigate the effect of this
glycan deletion on viral infectivity. Therefore, C8166
cells and U87.CD4.CXCR4.CCR5 cells were infected
with WT and mutant virus. C8166 cells express CD4
and CXCR4 and are therefore susceptible to infection by
NL4.3, IIIB and HE. U87.CD4.CXCR4.CCR5 cells express
CD4, CCR5 and CXCR4 and are susceptible to infection
by all investigated virus strains. The infection efficiency
was evaluated after 3 and 5 days respectively by deter-
mining the percentage of eGFP expressing cells using
flow cytometry (Figure 9). It was shown that the deletion
of the N616Q glycan resulted in a severe decrease in
viral infectivity of HIV-1NL4.3, HIV-1IIIB and HIV-1HE in
C8166 cells (Figure 9A). These data were confirmed
using U87.CD4.CXCR4.CCR5 cells (Figure 9B). In con-
trast, it was shown that the N616Q mutation in HIV-
1ADA had much more modest suppressive effects on viral
infectivity (not significant).
The infectivity of the mutant virus strains was also
evaluated based on their cytopathic effects on a U87.
CD4.CXCR4.CCR5 monolayer cell culture. As shown in
Figure 10, all WT viruses cause a cytopathic effect in the
monolayer while most mutant viruses do not visibly
affect the architecture of the monolayer, except N616Q
HIV-1ADA that was able to cause cytopathic effects simi-
lar to WT HIV-1ADA, which is in agreement with the
flow cytometry results (Figure 9B).0
20
40
60
80
100
120
NL4.3 IIIB HE ADA
In
fe
ct
iv
ity
 o
n 
C
81
66
,
re
la
tiv
e t
o 
W
T 
v
ir
us
WT
N616Q
A
** **
**
Figure 9 Infectivity of various HIV-1 strains containing the gp41 N616
were infected with WT and mutant gp41 virus particles of strains NL4.3, IIIB
determined using flow cytometric detection of eGFP expression in the infecte
corresponds to N614Q in HIV-1NL4.3, N616Q in HIV-1IIIB, N603Q in HIV-1HE and
experiments. The difference between WT and mutant gp41 virus was conside
t-test was <0.05 (* = p < 0.05, ** = p < 0.005).Based on the observation that HIV-1NL4.3 containing
the gp41 N616Q glycan deletion had a severely de-
creased viral infectivity (Figures 2, 3, 9) due to signifi-
cantly decreased levels of gp120 and gp41 in the viral
envelope (Figure 5), we studied the gp120 levels in the
other WT and N616Q mutant HIV-1 strains. As shown
in Figure 11, severely decreased gp120 levels were found
for mutant N616Q gp41 HIV-1 strains NL4.3, IIIB and
HE. This is in agreement with the decreased viral infec-
tivities observed for these mutant virus strains, as com-
pared to their WT counterparts. In contrast, the N616Q
gp41 mutant HIV-1ADA showed gp120 levels that were
comparable to the levels observed in WT HIV-1ADA.
This explains why the N616Q glycan deletion in gp41 of
HIV-1ADA did not result in a loss of viral infectivity.
Binding kinetics of CBAs against gp120 and gp41
It could be that gp41 glycans are involved in the inter-
action of CBAs with the viral particle, since long-term
exposure of virus to CBAs has led to the deletion of
most of the glycans in gp120 and the glycan N674 in
gp41 [11]. In order to determine whether CBAs are able
to target gp41, we used the SPR technology to study the
interaction of some of the CBAs (HHA, Urtica dioica
agglutinin (UDA), AH, 2G12) versus gp120 and gp41,
which were both covalently immobilized on a CM4 sen-
sorchip. It was shown that HHA, UDA, AH and 2G12
were able to bind gp120 in a concentration dependent
manner (Figure 12, left panels A, C, E and G, respect-
ively). HHA, UDA and AH were also able to efficiently
bind gp41 in a concentration dependent manner, while
2G12 failed to show a significant binding to gp41
(Figure 12, right panels B, D, F and H, respectively). A 1:1
binding model (suggesting the interaction of 1 ligand to 10
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d cells. The HIV-1HXB2 amino acid numbering was used (N616Q), which
N628Q in HIV-1ADA. Data are the means ± SEM of 2 independent
red to be significant when the p value calculated using the student’s
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Figure 10 The cytopathic effect of WT and mutant N616Q gp41 virus strains. U87.CD4.CXCR4.CCR5 cells were infected with WT and mutant
gp41 N616Q viruses of strains NL4.3, IIIB, HE and ADA. The cytopathic effect was evaluated after 5 days, using light microscopy.
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http://www.retrovirology.com/content/11/1/107analyte) was used to fit the obtained sensorgrams and re-
sulted in the determination of dissociation constants listed
in Table 1. It was shown that all compounds bound to
gp120 with a dissociation constant (KD) in the low nM
range. The binding of the compounds to gp41 was also
shown to have a KD in the low nM range, except for 2G12
which was not able to bind gp41 as already mentioned
above. The affinity of HHA to bind gp120 was about 1.5
times higher than the affinity towards gp41. For UDA, the
difference in binding to gp120 vs gp41 was a factor 2.4.
AH bound 6.8 times better to gp120 than to gp41.
In conclusion, the carbohydrate-binding compounds
HHA, UDA and AH were able to bind gp41 with KD’s in
the nanomolar range, although with a somewhat lower
affinity compared to binding to gp120. In contrast, the
monoclonal carbohydrate-specific antibody 2G12 solely
bound gp120 and showed a complete lack of affinity to-
wards gp41.
CBA susceptibility of WT and mutant gp41 virus strains
lacking individual gp41 glycans
After confirming the ability of some CBAs to bind gp41
in the SPR assay, we investigated the sensitivity of gp410
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Figure 11 Analysis of gp120 levels in the viral envelope of WT
and mutant N616Q gp41 virus strains. Relative protein levels
based on quantification of western blot data using the ImageJ
software, and presented as normalized to p24 levels. Data are the
means ± SD of 2 independent experiments.glycan-deleted HIV-1NL4.3 strains to CBAs to reveal the
influence of the lack of individual gp41 glycans on the
interaction between CBAs and the viral particle. We
made a selection of CBAs from different origins and
carbohydrate specificities (HHA, UDA, AH, 2G12 and
PRM-S) and, in addition, we also examined the mutant
virus sensitivity to the fusion inhibitor enfuvirtide (T-20)
and the CXCR4 antagonist AMD3100. The compounds
were investigated for their antiviral activity towards WT
and mutant (glycan-deleted) gp41 HIV strains in a cell-
free virus infection assay. All compounds were highly ac-
tive against WT HIV-1NL4.3, with EC50 values in the low
nanomolar (HHA, AH, 2G12, AMD3100), median nano-
molar (UDA), high nanomolar (T-20), or low micromo-
lar (PRM-S) range (Table 2). Based on these results, we
could conclude that none of the single gp41 N-glycan-
deletions had a significant effect on the eventual antiviral
activity of these compounds. In fact, only the mutant
gp41 N637Q virus strain proved most affected by the
test compounds, but this was consistently the case
against all compounds, including, beside CBAs, also the
bicyclam CXCR4 antagonist AMD3100 and the gp41-
binding agent T-20. This mutation is located in the HR2
domain of gp41, which is an important amino acid
stretch during the fusion process.
The effect of the N674D mutation in HIV-1 gp41
For the generation of glycan-deleted HIV-1 strains, we
decided to alter the glycosylated asparagine into the
structurally related glutamine, thereby eliminating glyco-
sylation with a predicted minimal influence on other
protein characteristics such as folding. However, during
the selection of HHA/2G12 resistant virus we obtained a
gp41 N-glycan deletion due to the N674D mutation, al-
tering the asparagine into an aspartic acid. To determine
the possible effect of this glycan deletion, we generated a
mutant HIV-1NL4.3 strain containing the N674D muta-
tion in gp41 and investigated the effect of this mutation
on viral infectivity and CBA susceptibility.
The N674D gp41 mutation resulted in an increased
viral infectivity (although not significant) (Figure 13). In
Figure 12 (See legend on next page.)
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Figure 12 SPR sensorgrams showing the binding and dissociation of CBAs to gp120 and gp41. For each compound, a two-fold dilution
series was tested and shown in different colors. The 1:1 binding model was used to fit the curves (shown in black). A. HHA vs gp120, highest
concentration: 10 nM. B. HHA vs gp41, highest concentration: 10 nM. C. UDA vs gp120, highest concentration: 80 nM. D. UDA vs gp41, highest
concentration: 80 nM. E. AH vs gp120, highest concentration: 80 nM. F. AH vs gp41, highest concentration: 80 nM. G. 2G12 vs gp120, highest
concentration: 500 nM. H. 2G12 vs gp41, highest concentration: 500 nM. The results represent one of at least 2 independent experiments.
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http://www.retrovirology.com/content/11/1/107Figure 3, similar results were obtained for the N674Q
mutant, which also showed a non-significant increase in
viral infectivity.
The N674D mutation in gp41 was shown to have
minor effects on CBA susceptibility (Table 3). It was
shown that this mutation resulted in a 2-fold resistance
towards HHA and an increased susceptibility towards
AH (2.5-fold) and T-20 (5.4-fold). These results differ
somewhat from the results obtained with the N674Q
gp41 HIV-1 mutant (Table 2). Regarding AH, 2G12 and
T-20, these mutants act opposite. While the N674Q
gp41 HIV-1 mutant was slightly phenotypically resistant
towards these compounds, the N674D mutation rather
increased the susceptibility of the mutant virus towards
these compounds.The effect of multiple gp41 glycan deletions on viral
infectivity and CBA susceptibility
We demonstrated that one single gp41 N-glycan deletion
in HIV-1 could have detrimental effects on viral infectivity
and that infectious mutant virus strains did not show a
markedly increased or decreased susceptibility towards
CBAs. However, pronounced CBA resistance generally
only occurs after the concomitant deletion of several
gp120 N-linked glycans. Therefore, we wondered whether
CBA sensitivity could be altered by deleting more than 1
gp41 N-glycan.
Combinations of 2, 3 and 4N-glycan deletions in gp41
were generated in HIV-1NL4.3. The infectivity of these
virus strains was investigated using C8166 cells. As can
be seen in Figure 13, many of the combined N-glycan
deletions in gp41 led to a severe loss in viral infectivity,
depending on the nature of the deleted N-glycans. No
combinations were made involving the N616Q glycan in
this study since this would most likely result in uninfec-
tious virus strains.Table 1 Kinetic data for the binding of CBAs to gp120
and gp41
Binding to gp120
(KD in nM)
Binding to gp41
(KD in nM)
Ratio binding to
gp120/gp41
HHA 0.5 ± 0.1 0.4 ± 0.1 1.5
UDA 9.0 ± 1.4 3.7 ± 0.3 2.4
AH 14 ± 1 2.0 ± 0.8 6.8
2G12 34 ± 6 No binding /
Average ± SD, based on at least 2 independent experiments.The mutant virus strains with sufficient residual viral in-
fectivity were investigated for their susceptibility towards
CBAs (Table 3). Some of the mutant virus strains showed
a minor decrease in susceptibility towards HHA and
UDA, although these effects were limited. The maximal
level of resistance observed was 3.1 for HHA (strain
N611Q/N637Q/N674Q) and 2.5 for UDA (strain N611Q/
N637Q). No susceptibility changes towards the non-
peptidic antibiotic PRM-S and the CXCR4 antagonist
AMD3100 were observed. For AH and 2G12 , minor
increased susceptibilities were found (up to 2.5-fold for
AH, 2.3-fold for 2G12). It was interesting to observe
that all mutant gp41 HIV-1 strains with double and
triple N-glycan deletions were markedly more sensitive
to the inhibitory activity of T-20 (up to 17-fold)
(Table 3). These data demonstrate that the antiviral acti-
vity of CBAs can slightly alter due to the absence of mul-
tiple gp41 N-glycans, however, this effect is only minor.
Discussion
As is the case for all known antiretroviral drug classes,
HIV tries to escape from the CBA inhibition pressure by
gaining drug resistance. Up till recently, solely N-glycan
deletions in gp120 were described to appear under CBA
pressure and N-glycan mutations in the ectodomain of
gp41 have never been described. However, we observed
the deletion of the gp41 glycan at N674 during the selec-
tion of mutant HIV-1NL4.3 exposed to the combination of
HHA and 2G12 in cell culture [11]. In the current
study, we aimed to gain more insight in the role of
gp41 N-linked glycans in the infectivity properties of
HIV-1 and the susceptibility of such mutant virus strains
to CBAs.
A single gp41 N-glycan deletion in HIV-1NL4.3 was
unable to provoke significant phenotypical resistance to-
wards the CBAs, although the deletion of some of the
gp41 glycans had a significant effect on the viral infectiv-
ity. We demonstrated that the intact glycosylation site
involving residue N616 of gp41 of HIV-1NL4.3 is absolutely
indispensable for the correct expression of the envelope
glycoproteins, the efficient binding to the primary receptor
CD4, the viral infectivity and transmission of DC-SIGN-
captured virus particles to CD4+ T-lymphocytes. In fact, a
highly decreased level of gp120/gp41 was detected in the
mutant gp41 N616Q HIV-1NL4.3 particle, resulting in a vir-
tually complete loss of sCD4 binding and thus complete
lack of infectivity/transmission potential when administered
Table 2 Inhibitory potential of a variety of HIV-1 inhibitors towards WT and mutant virus strains containing one
N-glycan deletion in gp41
HHA (nM) UDA (nM) AH (nM) 2G12 (nM) PRM-S (μM) T-20 (nM) AMD3100 (nM)
WT 0.9 ± 0.2 25 ± 3 5.2 ± 1.0 1.1 ± 0.2 4.8 ± 0.4 340 ± 141 3.5 ± 0.6
N611Q 1.6 ± 0.3 32 ± 6 5.4 ± 0.2 0.9 ± 0.2 5.3 ± 0.1 247 ± 177 2.5 ± 0.7
N625Q 1.4 ± 0.3 27 ± 5 8.1 ± 1.2 1.3 ± 0.2 4.5 ± 0.8 702 ± 255 2.9 ± 1.1
N637Q 3.7 ± 1.4 57 ± 24 15 ± 8 3.0 ± 2.0 5.3 ± 0.4 664 ± 454 7.6 ± 5.0
N674Q 1.3 ± 0.4 32 ± 11 8.3 ± 0.8 1.9 ± 0.5 5.2 ± 0.2 1530 ± 1201 3.8 ± 1.5
Values represent the EC50’s (50% effective concentration) of the test compounds expressed in nM or μM.
Data are the means ± SEM of at least 2 to 3 independent experiments.
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http://www.retrovirology.com/content/11/1/107to CD4+ T-lymphocyte cell cultures. Beside the gp41 N616
deletion, we also found that deletion of the N611 and N637
glycans had a somewhat suppressive effect on viral infectiv-
ity, which was however markedly less pronounced than in
the case of the gp41 N616 glycan deletion, and, opposite to
the gp41 N616 mutant virus, the gp41 N611 and N637 mu-
tant viral strains had normal CD4-binding properties and
envelope glycoprotein levels.
We confirmed the importance of the N616 N-glycan of
HIV-1NL4.3 gp41 in two other viral strains (HIV-1IIIB and
HIV-1HE). Strains IIIB and NL4.3 are both laboratory-
adapted HIV-1 strains that use the secondary CXCR4
receptor during virus entry, while strain HE is a clinical
isolate that can use both CXCR4 and CCR5 for entry.
However, the N616 glycan was found to be less crucial for
the infectivity of the CCR5-using laboratory-adapted HIV-
1ADA strain. The loss of viral infectivity for the mutant
HIV-1 strains NL4.3, IIIB and HE could be correlated to
severely decreased gp120 levels in their viral envelopes. In
contrast, the gp120 level in the envelope of mutant0
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Figure 13 Infectivity of HIV-1NL4.3 mutants containing the N674D mut
the single glycan-deleting N→ Q mutations in gp41, we also generated
The infectivity of these virus strains was studied using C8166 cells, which
7 consecutive days. The number of eGFP positive cells was quantified using
analysis, to quantifiy the infectivity of the virus strains. Data are the means ± S
mutant virus was considered to be significant when the p value calculated usN616Q gp41 HIV-1ADA did not significantly differ from
gp120 levels in WT HIV-1ADA. Therefore, we believe that
the decreased viral infectivity seen in the mutant N616Q
gp41 strains NL4.3, IIIB and HE was caused by a compro-
mised biosynthesis or trafficking of the envelope glycopro-
teins due to the N616Q glycan deletion in gp41. In this
respect, it should be noticed that mutant R5-tropic
N616A gp41 HIV-1 strains JR-CSF, JR-FL and BG505 kept
pronounced infectivity [24]. Whether these findings might
suggest that the N616 glycan in gp41 has a more import-
ant role for envelope glycoprotein synthesis and/or traf-
ficking with CXCR4-tropic viruses than CCR5-tropic
viruses need further investigation. However, when com-
paring our results with earlier published data on the gp41
N-linked glycans it seems that contradicting findings are
reported. Lee et al. [16] showed in 1992 that the N637
glycan was crucial for viral infection using the HXB2
strain, which was cloned from the IIIB isolate. They also
found a decreased viral infection when the N616 glycosyl-
ation site was mutated. However, it was postulated thatN611Q N625Q N637Q N674Q 
#1 x x 
#2 x x 
#3 x x 
#4 x x 
#5 x x 
#6 x x 
#A x x x 
#B x x x 
#C x x x 
#D x x x 
#I x x x x #C #D #I
** 
** ** 
ation or a combination of gp41 glycan deletions. In addition to
one N→ D mutation and several combinations of N→ Q mutations.
were infected at day 0. Subsequently, samples were harvested during
flow cytometry. The infection curves were used for linear regression
EM of 2–3 independent experiments. The difference between WT and
ing the student’s t-test was <0.05 (* = p < 0.05, ** = p < 0.005).
Table 3 Inhibitory potential of a variety of HIV-1 inhibitors towards WT and mutant virus strains containing the N674D
mutation or a combination of glycan deletions in gp41
Nr HHA (nM) UDA (nM) AH (nM) 2G12 (nM) PRM-S (μM) T-20 (nM) AMD3100 (nM)
WT 0.9 ± 0.2 25 ± 3 5.2 ± 1.0 1.1 ± 0.2 4.8 ± 0.4 340 ± 141 3.5 ± 0.6
N674D 1.9 ± 0.6 34 ± 10 2.1 ± 0.5 0.8 ± 0.2 4.7 ± 0.4 63 ± 20 3.3 ± 0.3
N611Q/N637Q #2 2.7 ± 0.4 63 ± 7 3.0 ± 0.7 0.5 ± 0.1 4.8 ± 0.4 49 ± 4 3.5 ± 0.3
N625Q/N637Q #4 1.4 ± 0.2 51 ± 6 3.8 ± 0.1 0.8 ± 0.2 5.3 ± 0.1 21 ± 2 3.3 ± 0.4
N625Q/N674Q #5 1.3 ± 0.3 30 ± 2 3.2 ± 0.3 0.9 ± 0.1 5.3 ± 0.1 57 ± 4 3.5 ± 0.1
N637Q/N674Q #6 1.6 ± 0.5 28 ± 10 4.3 ± 0.9 0.9 ± 0.0 5.3 ± 0.1 48 ± 24 3.6 ± 0.3
N625Q/N637Q/N674Q #B 2.1 ± 0.1 35 ± 6 3.2 ± 0.7 0.5 ± 0.1 5.0 ± 0.1 20 ± 2 3.5 ± 0.3
N611Q/N637Q/N674Q #C 2.8 ± 0.6 52 ± 7 3.6 ± 0.4 0.6 ± 0.0 5.3 ± 0.2 56 ± 10 3.3 ± 0.2
Values represent the EC50’s (50% effective concentration) of the test compounds expressed in nM or μM.
Data are the means ± SEM of at least 3 independent experiments.
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instead of the N616 glycan deletion [16]. The same year,
Dedera et al. [17] found that both the N611 and N616 gly-
cans were crucial for syncytium formation and viral infec-
tion of HXB2. In addition, they also found that the N637
glycan was important for viral infection [17]. Dash et al.
[20] published in 1994 that the N637 glycan of gp41 was
the most important glycan for viral function, using a virus
strain (pEVd1443) that is related to the NL4.3 strain.
Deleting this glycan was shown to result in a deficient en-
velope glycoprotein expression [20]. In 1998, it was shown
by Perrin et al. that the N616 glycan was crucial for the
infectivity of the X4 strain BH10 [19]. Recently, Wang
et al. demonstrated that the presence of an intact N616
glycan was important for the infectivity of the FE strain,
while this glycan deletion had no effect on the infectivity
of strains YU-2 and Sc19-15 [18]. In conclusion, the gp41
glycans at positions N611, N616 and N637 have all been
shown to be important for viral infectivity, but the pre-
dominant N-glycan seems to be dependent on the viral
strain or the employed experimental procedures. Although
we found the N616 glycan to be the most important glycan
in gp41 for viral infectivity, we also found a decreased viral
infectivity in case of mutations N611Q and N637Q as
reported by several other researchers.
Mutating the gp41 N616 glycosylation site did only
moderately reduce the capture efficiency by Raji/DC-
SIGN cells (~20%), although reducing the envelope glyco-
protein levels by ~85%. Similar results were obtained for
at least one gp120 glycan-deletion (N156Q mutation in
the V1/V2 region), where gp120/gp41 levels were reduced
by 75% in the virus particle whereas the capture efficiency
was unaffected (unpublished observations). We therefore
may hypothesize that the interaction between DC-SIGN
and gp120 is so highly efficient that even a highly reduced
level of envelope glycoprotein expression (up to 85%) can
still result in a capture efficiency comparable to WT virus.
Alternatively, it is also possible that there is too much
gp120 present in the HIV particle to be bound by a limitednumber of DC-SIGN molecules. A decrease in envelope
glycoprotein expression would then only result in a se-
verely compromised virus capture when the remaining
levels of gp120/gp41 in the envelope are at least >85%
lower than those observed in WT virus particles.
The N674D mutation that appeared in virus strains
from the selection experiments using a combination of
HHA and 2G12 could possibly be a rescue mutation. It
was found that HHA/2G12-resistant virus suffered from
a severe decrease in viral infectivity [11]. However, here
we show that the N674D glycan deletion led to an in-
crease (though non-significant) in the infectivity of HIV-
1NL4.3. We therefore cannot exclude that the appearance
of the N674D mutation in a background of gp120 muta-
tions was merely a secondary mutation aiming to increase
the infectivity of the resistant virus strain again, instead of
a mutation that was directly the consequence of targeted
pressure by HHA/2G12 and meant to increase the drug
resistance level.
Our data also demonstrate that deletion of gp41 N-linked
glycans did not significantly influence the susceptibility of
HIV-1NL4.3 to CBAs. As earlier shown for gp120 by SPR
technology, we now also showed that the CBAs were able
to markedly bind to gp41, indicating that gp41 can be effi-
ciently targeted by CBAs. However, on the virus particle,
gp120 masks gp41 and may therefore hinder the interaction
of CBAs with gp41. Only after gp120 has been bound to its
CD4 receptor, conformational changes in gp120 induce the
transient exposure of gp41. This could explain why, al-
though CBAs are able to bind gp41, they are only rarely
found to induce gp41 N-glycan deletions under long-term
drug selection pressure. Thus, whereas gp41 might be a
target for CBAs in HIV-infected cell cultures, these agents
probably do not efficiently reach gp41 for interaction
because the entry process of the virus is already blocked by
the interaction of the CBAs with gp120. However, only in
those cases where the virus can escape this CBA gp120-
interaction blockade, the CBAs can eventually block the
second CBA-susceptible step in the fusion process as well.
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efficiently and independently interact with two subse-
quent steps in the virus infection process, making them
potentially very efficient drug candidates.
Conclusion
We revealed the importance of some of the gp41 N-linked
glycans, in particular at position N616. It was shown that
the N616Q mutation in gp41 resulted in severely decreased
gp120 levels in the viral envelopes of HIVNL4.3, HIV-1IIIB
and HIV-1HE, afforded markedly decreased CD4-binding
by HIV-1NL4.3 and significantly decreased the infectivity of
these viral strains. In addition we showed that, although
CBAs have a pronounced affinity for gp41 glycans, their
main primary target for viral inhibition is most likely
gp120 rather than gp41.
Methods
Compounds
The high-mannose binding plant lectin GNA, derived
from Galanthus nivalis, and the N-acetylglucosamine-
specific plant lectin UDA, derived from Urtica dioica,
were kindly provided by Prof. E. Van Damme (Ghent,
Belgium). AH derived from the actinomycete K97-0003
was provided by H. Tanaka (Fukushima, Japan). The
monoclonal antibody 2G12 was purchased from Poly-
mun Scientific (Vienna, Austria). PRM-S was obtained
from Prof. T. Oki and Prof. Y. Igarashi (Toyama, Japan).
T-20 was kindly provided by the AIDS Research Alliance
(Los Angeles, CA). AMD3100 was a kind gift of Dr.
Gary Bridger (AnorMED, Langley, Canada) or obtained
from Sigma-Aldrich (St. Louis, MO).
Cells
Human CD4+ T lymphocytic C8166 cells were obtained
from the American Type Culture Collection (ATCC)
(Manassas, VA). Human Raji/DC-SIGN B-lymphocytic cells,
expressing DC-SIGN, were constructed by Geijtenbeek
et al. [25] and were kindly provided by Dr. L. Burleigh
(Institut Pasteur, Paris, France). Both cell lines were grown
in RPMI-1640 medium (Invitrogen, Merelbeke, Belgium),
supplemented with 10% fetal calf serum (FCS) (Sigma,
Bornem, Belgium), 2 mM L-glutamine and 2% gentamicin
(Invitrogen).
Human embryonal kidney cells (HEK293T) were ob-
tained from ATCC and were grown in Dulbecco’s
Modified Eagle Medium (DMEM) (Invitrogen), sup-
plemented with 10% FCS (Sigma), 75 mM NaHCO3
and 2% gentamicin (Invitrogen).
Microglial U87.CD4.CXCR4.CCR5 cells were provided
by Professor D. Schols (Leuven, Belgium) and their con-
struction and characterization are described elsewhere
[26]. These cells were grown in DMEM supplemented
with 10% FCS (Sigma), 75 mM NaHCO3, 0.002%gentamicin (Invitrogen), 0.0001% puromycin (Invitrogen)
and 0.02% geneticin (Invitrogen).
HeLa-tat-III cells were obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH:
HeLa-tat-III were originally constructed by Drs. William
Haseltine, Ernest Terwilliger and Joseph Sodroski
[27,28]. The cells were grown in DMEM medium (Invitro-
gen), supplemented with 10% FCS (Sigma), 75 mM
NaHCO3, 2% gentamicin and 0.02% geneticin (Invitrogen).
Plasmids
The construct pNL4.3_ΔEnv_eGFP was kindly pro-
vided by Dr. M.E. Quiñones‐Mateu (Lerner Research
Institute, Cleveland, OH) [29]. This construct encodes all
HIV-1NL4.3 genes except the gp160 envelope gene. In
addition, this construct also encodes eGFP.
The construct pNLHIVxΔUΔss, was a kind gift from
Alenka Jejcic (at that time at the Karolinska Institute,
Stockholm, Sweden) and allows the production of HIV-
1NL4.3 particles lacking envelope glycoprotein expression.
The plasmid pBlue_Env(NL4.3) was used to amplify the
gp160 gene of HIV-1NL4.3 for transfection purposes and
was used for the cloning of pBlue_Env(IIIB), pBlue_Env
(ADA) and pBlue_env(HE). Therefore, viral RNA was har-
vested for strains IIIB, ADA and HE using the QIAamp
Viral RNA mini kit (Qiagen). The gp160 genes were amp-
lified using the primers EnvB_EcoRI and HIV8726R_XhoI
(Additional file 2: Table S1) and subsequently inserted in
the pBlue backbone, to replace the NL4.3 gp160 gene.
Viruses
HIV-1 was produced as described previously [30].
Briefly, HEK293T cells were cotransfected with a DNA
construct encoding WT or mutant gp160 and XbaI-
linearized pNL4.3_ΔEnv_eGFP. This leads to homolo-
gous recombination, thereby inserting the gp160 gene
in the pNL4.3_eGFP backbone. Therefore, the HIV-1-
infected cells express eGFP. The WT and mutant gp160
genes of four HIV-1 strains (NL4.3, IIIB, ADA and HE)
were used to generate recombinant viruses. In this way,
recombinant HIV-1NL4.3 was generated, as well as hy-
brid virus strains containing all NL4.3 genes except for
the gp160 envelope gene which originated from HIV-
1IIIB, HIV-1ADA or HIV-1HE.
HIV-1NL4.3 lacking envelope glycoprotein expression
was produced by transfecting HeLa-tat-III cells with the
construct pNLHIVxΔUΔss. Transfection was performed
using GeneCellIn (BioCellChallenge, Nivelles, Belgium),
according the instructions of the manufacturer.
Site-directed mutagenesis
Mutations were introduced in the HIV-1 gp160-
encoding plasmids pBlue_Env(NL4.3), pBlue_Env(IIIB),
pBlue_Env(ADA), and pBlue_Env(HE). Therefore, we
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(Agilent Technologies, Diegem, Belgium) and the
primers listed in Additional file 2: Table S1. Plasmid
DNA was purified using the PureLink Quick Plasmid
Miniprep Kit (Invitrogen) and sequenced with the ABI
PRISM BigDye Terminator v3.1 Ready Reaction Cycle
Sequencing Kit (Applied Biosystems, Ghent, Belgium)
to confirm the presence of the desired mutations. The
obtained amplicons were loaded onto the ABI3100
Genetic Analyzer (Applera, Nieuwekerk a/d Issel, The
Netherlands) after which the sequences were analyzed
using the Geneious Pro 5.5.6 software.
The oligonucleotide sequences of the sequencing
primers, of which some have been published before [31],
are listed in Additional file 2: Table S1.
Microscopic evaluation of syncytium formation and eGFP
expression
Hundred thousand C8166 cells were seeded into wells of
a 96-well plate and were infected with 4 ng p24 of WT
or gp41 N-glycan-deleted HIV-1NL4.3, in a total volume
of 200 μl per well. Three days post infection, giant cell
formation and eGFP expression was visualized using the
FLoid Cell Imaging System (Life Technologies, Ghent,
Belgium).
Quantitative determination of the infectivity potential of
the mutant gp41 virus strains
Two approaches were used to quantitatively analyze
virus infectivity.
One experiment was performed as described previously
[11]. Briefly, 106 C8166 cells were brought into wells of a
24-well plate and were infected with 40 ng p24 of WT or
mutant gp41 HIV-1NL4.3 on day 0. By adding RPMI-1640
culture medium it was ascertained that every well con-
tained a total volume of 2 ml. Every day, for 7 subsequent
days, samples were harvested, fixed with 3% formaldehyde
and stored at 4°C for further analysis. At the end of the in-
cubation period, the percentage of infected cells was
quantified for all samples by the analysis of eGFP expres-
sion with a FACS CantoII flow cytometer (BD biosciences,
Erembodegem, Belgium). The data were analysed by FACS
Diva Software (BD biosciences).
Alternatively, the viral infectivity of several WT and
mutant gp41 N616Q virus strains was compared using
C8166 and U87.CD4.CXCR4.CCR5 cells. Therefore,
30,000 C8166 and 7,000 U87.CD4.CXCR4.CCR5 cells
were seeded in a 96 well plate. The C8166 cells were im-
mediately exposed to 2,500, 1,250 or 625 pg p24 of the
different virus strains. After 3 days, the C8166 cells were
fixed in 3% formaldehyde and eGFP expression was ana-
lyzed using flow cytometry (FACS CantoII, BD biosci-
ences). For the U87.CD4.CXCR4.CCR5 cells, infection
was initiated 1 day after cell seeding and was evaluatedmicroscopically (FLoid Cell Imaging System, Life
Technologies) and by flow cytometry (FACS CantoII,
BD biosciences) after 5 days.
Quantification of mutant gp41 virus binding to sCD4
The experiment was performed as published before,
although some adaptations were made [32]. Briefly, 8-well
maxisorp strips (Nunc, Haasrode, Belgium) were coated
for 2 hours at room temperature with 0.5 μg of soluble
CD4 (Sino Biological Inc, Ghent, Belgium) in 50 mM car-
bonate buffer (pH 9.6). After washing with wash buffer
(PBS supplemented with 0.05% Tween 20), the wells were
blocked for 1 hour at room temperature using PBS pH 7.4
supplemented with 0.05% Tween 20 and 2% milk powder
(= blocking buffer). After a next round of washing, ap-
proximately 48 ng p24 of virus lysed using 10% Triton-
X100 in blocking buffer was added to the wells for 1 hour
at 37°C. After washing, the wells were incubated with the
primary sheep antibody directed against gp120 (D7324;
Aalto Bio Reagents, Dublin, Ireland) in blocking buffer
during 1 hour at 37°C. Afterwards, the wells were washed
again and incubated for 1 hour at 37°C with the secondary
antibody labelled with alkaline phosphatase in blocking
buffer. Substrate buffer (1 mg/ml p-nitrophenyl phosphate
(Sigma) dissolved in 10% diethanolamine, pH 9.8, with 0.5
MgCl2) was added to the wells after sufficient washings.
Following 30 minutes incubation, the absorbance at
405 nm was determined using the Safire 2 microtiter plate
reader (Tecan, Mechelen, Belgium).
Western blot analysis to quantify env incorporation in the
viral particles
The expression and incorporation levels of the envelope
glycoproteins gp120 and gp41 in WT and mutant gp41
virus particles were determined by Western blot (WB)
analysis as described previously [32]. 50 ng of p24 virus
was loaded onto a 4-12% Bis-Tris PAGE gel (Invitrogen).
After blotting, gp120, gp41 and p24 were detected using
the primary antibodies PAI-7218 (Thermo Scientific,
Erembodegem, Belgium), C8 and AB9044 (Abcam,
Antwerp, Belgium), respectively. The monoclonal anti-
body directed to gp41, C8, was derived from HIV-1 gp41
Hybridoma (Chessie 8) cells and obtained through the
NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH, from Dr George Lewis [33]. Visualization was
achieved by using secondary, horseradish peroxidase-
labelled antibodies (Santa Cruz Biotechnology, Boechout,
Belgium) and the SuperSignal West Pico Chemilumines-
cent Substrate Kit (Thermo Scientific). Imaging was per-
formed using the BioRad ChemiDoc MP Imager (BioRad,
Nazareth Eke, Belgium). The ImageJ software was used
for quantification of the WB data. MagicMark XP
Western protein standard (Novex) was used to confirm
the molecular weight of gp120, gp41 and p24.
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HIV-transfected HEK293T cells using flow cytometry
This experiment was performed as described earlier [34].
HEK293T cells were transfected to produce WT or mu-
tant HIV-1NL4.3. Two or three days post transfection, the
cells were stained to detect surface gp120 using the mono-
clonal antibody 2G12 and a secundary antibody labelled
with Alexa Fluor 647 (Invitrogen). The cells were analysed
using the FACSCanto II flow cytometer (BD Biosciences).
Capture of HIV-1NL4.3 particles by Raji/DC-SIGN cells and
the subsequent transmission of DC-SIGN-captured virions
to C8166 cells
Wild-type and gp41 mutant HIV-1NL4.3 virus strains
(50,000, 25,000 and 12,500 pg p24) were incubated with
106 Raji/DC-SIGN cells for 1 h at 37°C in a volume of
1 ml, after which unbound virions were removed by
thorough washings. The cells were resuspended in 1 ml
of fresh culture medium and the amount of captured
virions was determined using a p24 ELISA (PerkinElmer,
Boston, MA). In parallel, 2x105 virus-captured Raji/DC-
SIGN cells were brought into contact with 2x105 C8166
cells in a volume of 1 ml, resulting in the transmission
of virions from the Raji/DC-SIGN cells to the C8166
cells and the subsequent infection of the C8166 cells.
After 72 h of cocultivation, the formation of syncytia
was evaluated microscopically and the amount of virus
produced by the C8166 cells was determined by a p24
ELISA (PerkinElmer). The measured viral load was used
as a parameter for the efficiency of transmission of virus
from Raji/DC-SIGN cells to C8166 cells.
Studying the binding kinetics of CBAs to gp120 and gp41
The SPR technology was used to study the interaction of
a selection of CBAs (including 2G12) with gp120 and
gp41. Therefore, gp120, gp41 and human serum albumin
(HSA) were covalently bound to the surface of a CM4
chip (GE Healthcare, Uppsala, Sweden), at densities of
approximately 115, 45 and 71 RU, using standard amine
coupling. These low densities of immobilized ligands are
necessary to prevent rebinding during the dissociation
phase. HSA was used as a negative control, to take into
account random protein-protein interactions. The inter-
action studies were performed using the Biacore T200
instrument (GE Healthcare), at a temperature of 25°C
and with HBS-P (10 mM HEPES, 150 mM NaCl and
0.05% surfactant P20; pH 7.4) supplemented with
10 mM CaCl2 as running buffer. For each compound, a
two-fold serial dilution was used with the highest CBA
concentrations being 10 nM for HHA, 80 nM for UDA,
80 nM for AH and 500 nM for 2G12. Association was
monitored during a 2 minute injection phase, at an
injection rate of 30 μl/min. Afterwards, dissociation was
monitored during 5 minutes. Residual bound analytewas eliminated by a regeneration step using 50 mM
NaOH (in the case of HHA, UDA and AH) or Glycine-HCl
pH 1.5 (in the case of 2G12) during 10 seconds at a rate of
30 μl/min. The obtained sensorgrams were used to perform
a kinetic analysis, based on the 1:1 Langmuir binding model
(GE Healthcare), resulting in KD values for the studied
CBA-(glyco)protein interactions.Determination of the sensitivity of the mutant gp41 virus
strains for CBAs
Thirty thousand C8166 cells were brought into wells of a
96-well plate, in a total volume of 200 μl. The test com-
pounds (HHA, UDA, AH, 2G12, PRM-S, T-20 and
AMD3100) were added as a 5-fold serial dilution with the
highest concentrations of 0.2, 2.3, 0.3, 0.2, 60, 3.3, 0.3 μM,
respectively. WT or mutant HIV-1NL4.3 were added at
viral loads resulting in approximately 10% eGFP positive
cells at 72 hours post infection. After incubation at 37°C
for 72 hours, the cells were fixed in 3% formaldehyde and
analysed using the FACS CantoII flow cytometer (BD bio-
sciences) to quantify eGFP expression as a measurement
of viral infectivity. The 50%-effective concentration (EC50)
was calculated as the compound concentration required
to suppress viral infection by 50%.Statistics
A Student’s t-test was used to validate the significance of
the data. A p value <0.05 was considered as significant.Additional files
Additional file 1: Figure S1. Original Western blot images used to
generate Figure 5A. Images generated using Image Lab (Biorad) after an
exposure of 8 s (A), 32 s (B) and 82 s (C). Image A was used for the
visualization of p24, image B was used for the visualization of gp120,
Image C was used for the visualization of gp41. M; MagicMark XP
Western protein standard (Novex).
Additional file 2: Table S1. Oligonucleotide sequences of the primers
used for cloning, site-directed mutagenesis and sequencing of gp41.Abbreviations
AH: Actinohivin; CBA: Carbohydrate-binding agent; EC50: 50% effective
concentration; eGFP: Enhanced green fluorescent protein; ELISA: Enzyme-linked
immunosorbent assay; GNA: Galanthus nivalis agglutinin; HHA: Hippeastrum
hybrid agglutinin; HR: Heptad repeat; KD: Dissociation constant;
PRM-S: Pradimicin-S; sCD4: Soluble CD4; UDA: Urtica dioica agglutinin;
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